GTC—NVIDIA today announced that it is collaborating with Medtronic, the world’s largest healthcare technology provider, to accelerate the development of AI in the healthcare system and bring new AI-based solutions into patient care. The companies will integrate NVIDIA healthcare and edge AI technologies into Medtronic’s GI Genius™ intelligent endoscopy module, developed and manufactured by Cosmo Pharmaceuticals. GI Genius is the first FDA-cleared, AI-assisted colonoscopy tool to help physicians detect polyps that can lead to colorectal cancer. GI Genius has been designed to host a suite of AI algorithms and integrating the NVIDIA Clara™ healthcare platform could allow Medtronic to scale…
Author: Praveen Suthrum
The combination of decreased physician reimbursements and increased procedure costs continues to put physician pay in peril. Linda Lee, MD, medical director of endoscopy at Brigham and Women’s Hospital in Boston, recently connected with Becker’s to discuss the challenges gastroenterologists face regarding reimbursement rates for GI procedures.
– Vivante Health, a provider of digital digestive health solutions for employers and health plans, is expanding its GIThrive platform with enhanced technology that optimizes triage, telemedicine appointments with physicians in every state when needed, and more – GIThrive’s virtual care model will now be powered by enhanced technology that facilitates triage, including access to all existing GIThrive features plus GI-related test ordering, prescriptions and telemedicine appointments with physicians in every state for members needing such support. – Users will now receive AI-driven, personalized care plans guided by an expert team of coordinated care providers including gastroenterologists, internal medicine specialists,…
Computer-aided detection (CADe) during colonoscopy may not lead to major improvements in key measures, particularly in community-based settings, according to a new study. In a randomized clinical trial using EndoVigilant, there wasn’t a significant difference in adenomas per colonoscopy (APC) in procedures with the CADe tool versus those without it. In addition, the adenoma detection rate (ADR) and serrated polyp detection rate were similar in the CADe and non-CADe groups. “Although we were disappointed that AI [artificial intelligence] did not improve detection of adenomas or serrated polyps in our study, we are still optimistic that this exciting technology will eventually…
With recent data highlighting the emotional and social challenges of inflammatory bowel disease, AGA has launched the My IBD Life campaign to address the growing need for psychosocial support in patient care. According to an AGA press release, survey results from 1,026 patients with IBD aged 18 to 59 years found that nearly two-thirds reported comorbid conditions, with more than one in three reporting a diagnosis of anxiety (36%) or depression (35%) — rates “well above” the U.S. averages of 19% and 8%, respectively.
A negative result on a screening colonoscopy appears to be highly predictive of no colorectal cancer even when screening intervals exceed 10 years, according to a recent large study. The finding suggests it may be safe to extend the currently recommended screening interval beyond 10 years in patients with a negative exam, particularly those considered to be at low risk. “This is a very positive study because it really demonstrates the protective power of colonoscopy for substantial periods of time,” said Douglas K. Rex, MD, MASGE, a distinguished professor emeritus at the University of Indiana School of Medicine, in Indianapolis.
No matter how confident an investor feels in thier current portfolios, it’s impossible not to be shaken by certain headlines. In the recent days physician clients of our firm have been concerned and reaching out to me seeking advice if they should move their money out of the local banks to larger banks.
mbiomics GmbH, a German microbiome biotech company developing the first generation of effective microbiome-based therapeutics has closed €13 million ($ 15 million) of a series A financing round led by MIG Capital. High-Tech Gründerfonds and Bayern Kapital joined the funding round together with a pool of private seed investors. mbiomics uses its proprietary, tailored high-resolution profiling platform and computational techniques to generate precision data on microbiota modulation. The technology provides an improved understanding of the complex interactions between the gut microbiome and the host, allowing mbiomics to design more effective microbial consortia that can be delivered to patients as precision…
Digital therapeutics (DTx), which provide evidence-based interventions through software programs, could benefit patients with nonalcoholic fatty liver disease (NAFLD), according to a new review. Few studies have directly focused on DTx for NAFLD, but recent research about lifestyle interventions delivered via smartphone apps or web-based platforms could point to future possibilities, the authors write. “Although lifestyle interventions have been shown to result in positive outcomes among patients with NAFLD, the success rate of the interventions and the sustainability of a healthy lifestyle for patients are issues that need to be addressed,” Junping Shi, MD, PhD, a professor of medicine at…
Functional gastrointestinal (GI) disorders, also called disorders of gut-brain interaction (DGBI), are a common group of conditions that can cause various symptoms, including abdominal pain, bloating, constipation, and diarrhea. These symptoms can significantly impact a patient’s quality of life, and effective diagnosis and treatment require a multidisciplinary approach. The first step in diagnosing a functional GI disorder is to obtain a thorough medical history and conduct a physical exam. Diagnostic tests, including hydrogen and methane breath tests, blood tests, stool tests, or imaging studies, may be ordered depending on the patient’s symptoms. Once confirming a diagnosis, a multidisciplinary team can…